Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


X0202 SCHEDULE 13D/A 0001104659-25-024530 0001231517 XXXXXXXX LIVE 1 Common Stock, par value $0.0001 per share 03/27/2026 false 0001854270 81726A100 Senti Biosciences, Inc. 2 Corporate Drive First Floor South San Francisco CA 94080 Bayer HealthCare LLC 862-404-3000 100 Bayer Boulevard Whippany NJ 07981 0001231517 N Bayer HealthCare LLC b OO N DE 0.00 6142848.00 0.00 6142848.00 6142848.00 N 17.82 CO The amounts reported in rows 8, 10 and 11 herein include the number of shares of Issuer Common Stock that would be issuable upon the exercise in full of the warrant for Issuer Common Stock held by Bayer Healthcare LLC (the "Warrant"). The amount reported in row 13 herein includes 3,333,000 shares of Issuer Common Stock underlying the Warrant that is exercisable in full within 60 days of the date of this filing. 0001965754 N Bayer US Holding LLC b OO N DE 0.00 6142848.00 0.00 6142848.00 6142848.00 N 17.82 CO The amounts reported in rows 8, 10 and 11 herein include the number of shares of Issuer Common Stock that would be issuable upon the exercise in full of the Warrant. The amount reported in row 13 herein includes 3,333,000 shares of Issuer Common Stock underlying the Warrant that is exercisable in full within 60 days of the date of this filing. Y Sebastian Guth b OO N XX 0.00 6142848.00 0.00 6142848.00 6142848.00 N 17.82 IN The amounts reported in rows 8, 10 and 11 herein include the number of shares of Issuer Common Stock that would be issuable upon the exercise in full of the Warrant. The amount reported in row 13 herein includes 3,333,000 shares of Issuer Common Stock underlying the Warrant that is exercisable in full within 60 days of the date of this filing. Y Priyal Patel b OO N XX 0.00 6142848.00 0.00 6142848.00 6142848.00 N 17.82 IN The amounts reported in rows 8, 10 and 11 herein include the number of shares of Issuer Common Stock that would be issuable upon the exercise in full of the Warrant. The amount reported in row 13 herein includes 3,333,000 shares of Issuer Common Stock underlying the Warrant that is exercisable in full within 60 days of the date of this filing. Common Stock, par value $0.0001 per share Senti Biosciences, Inc. 2 Corporate Drive First Floor South San Francisco CA 94080 Bayer HealthCare LLC ("BHC"); Bayer US Holding LLC ("BUSH LLC"); Sebsatian Guth ("Guth") and Priyal Patel ("Patel", together with Guth, the "Managers of BUSH LLC" and collectively, the Managers of BUSH LLC, along with BHC and BUSH LLC, the "Reporting Persons"). BHC - Delaware BUSH LLC - Delaware Guth - Unknown Patel - Unknown BHC - 17.82% BUSH LLC - 17.82% Guth - 17.82% Patel - 17.82% Each Reporting Person disclaims beneficial ownership of the shares other than those shares which such person owns of record. The percentage of outstanding Issuer Common Stock which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person's cover sheet. Such percentage was calculated based on 31,144,497 shares of Issuer Common Stock reported to be outstanding as of March 19, 2026 on the Issuer's Annual Report on Form 10-K for the period ended December 31, 2025, as filed with the SEC on March 27, 2026. Regarding the number of shares as to which such person has: (i) sole power to vote or to direct the vote: See line 7 of cover sheets. (ii) shared power to vote or to direct the vote: See line 8 of cover sheets. (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets. (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets. Exhibit 7.01 - Joint Filing Agreement by and among the Reporting Persons (incorporated by reference to Exhibit 7.01 of the Schedule 13D filed with the SEC on March 17, 2025). Exhibit 7.02 - Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended (incorporated by reference to Exhibit 7.02 of the Schedule 13D filed with the SEC on March 17, 2025). Exhibit 7.02(a) - Power of Attorney regarding filings under the Securities Exchange Act of 1334, as amended. Exhibit 7.03 - Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Issuer's Current Report on Form 8-K (File No.001-40440), filed on December 2, 2024). Exhibit 7.04 - Form of Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.1 to the Issuer's Current Report on Form 8-K (File No.001-40440), filed on December 2, 2024). Exhibit 7.05 - Form of Securities Purchase Agreement, dated December 2, 2024, by and among Senti Biosciences, Inc. and the purchasers named therein (incorporated by reference to Exhibit 10.1 to the Issuer's Current Report on Form 8-K (File No.001-40440), filed on December 2, 2024). Exhibit 7.06 - Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to the Issuer's Current Report on Form 8-K (File No.001-40440), filed on December 2, 2024). Bayer HealthCare LLC /s/ Priyal Patel Priyal Patel, President 04/16/2026 Bayer US Holding LLC /s/ Sebastian Guth Sebastian Guth, President 04/16/2026 Sebastian Guth /s/ Sebastian Guth Sebastian Guth 04/16/2026 Priyal Patel /s/ Priyal Patel Priyal Patel 04/16/2026